Sagimet develops denifanstat, an oral FASN inhibitor, in a U.S. Phase 3 for acne; it is not approved in the U.S., and its China partner Ascletis has an application under review there.
Denifanstat, a once-daily oral FASN inhibitor, met all endpoints in Ascletis's Chinese Phase 3 in acne (treatment success 33.2% vs 14.6%), and China's regulator is reviewing it. Sagimet's U.S. Phase 3, AURORA (about 800 patients), dosed its first patient in October 2026 and reads out in the second half of 2027. TVB-3567, a follow-on, starts Phase 2 by year-end. A $115 million offering extended cash through mid-2029.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: AURORA confirms efficacy
Does denifanstat beat placebo on all three co-primary acne endpoints in U.S. patients?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Sagimet's U.S. acne Phase 3 has started; results come in 2H 2027
Partner's Phase 3 win validates denifanstat's acne mechanism; U.S. AURORA readout decides whether that translates to an FDA-approvable label
Denifanstat's Phase 3 acne win in China now needs a US AURORA replication to unlock an NDA — watch whether FDA accepts the same drug in a different population
Partner-validated Phase 3 acne data now drives Sagimet's US pivotal bet, contingent on FDA alignment on trial design
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Liver and digestive diseases, Skin diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.